You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
興科蓉醫藥(06833.HK)年度純利增加14.4%至1.35億元
格隆匯 03-31 07:29

格隆匯3月31日丨興科蓉醫藥(06833.HK)發佈公吿,截至2021年12月31日止年度,集團的收益約為人民幣20.241億元,毛利增加人民幣9120萬元至人民幣3.65億元,毛利率則由2020年的13.4%增加至報吿期內的18.0%。毛利率的增加受益於人血白蛋白銷售價格比去年高。報吿期內,集團純利增加14.4%至人民幣1.35億元,主要是由於集團的銷售毛利增加。公司擁有人應占純利為人民幣1.35億元,純利額增加人民幣1700萬元。每股基本及攤簿盈利為人民幣0.08元。

公吿表示,集團與中國中醫科學院中藥研究所訂立合作協議,開發以雄黃為原料的化學藥物“SincoI”,是以雄黃為原料的用於治療急性早幼粒細胞白血病的新型藥物,以期將集團業務向上遊延伸的同時,未來將該治療領域的新藥提供給患者。目前處於中試試驗。報吿期內,集團產生開發SincoI的研發費用為人民幣700萬元。

集團與北京諾康達醫藥科技股份有限公司就開發注射用聚己內酯微球面部填充劑(“少女針”)及其材料訂立了主合作協議及技術開發協議。此次與北京諾康達合作開發的少女針,以Ellansé®為對照,從產品配方到製備技術分析上採用生物醫用材料基質的PCL和CMC,開發半永久性可注射填充產品。後續集團將依託聚己內酯原材料開發系列產品“PCL+X”,衍生出多種醫美產品,適用於各種部位。研發總費用為人民幣8850萬元。預計技術開發項目將於49個月內完成。報吿期內,集團產生的研發費用為人民幣2550萬元。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account